泌尿外科威廉亚洲博彩公司

MedSci主页 / 所有栏目 / 泌尿外科威廉亚洲博彩公司

合理应用药物治疗前列腺炎的临床专家意见

2018-12-30 中国泌尿外科相关专家组(统称) 中国中西医结合外科杂志.2018,24(6):812-814.

Ⅰ型和Ⅱ型前列腺炎主要由病原体感染引起。慢性细菌性前列腺炎患者的临床分离株中,约85% 具有形成生物膜的能力。生物膜能粘附于前列腺小管上皮细胞,显著减弱了抗生素治疗的效果,成为病原体持续存在和感染复发的重要原因。Ⅰ型前列腺炎应及早进行抗感染治疗。Ⅱ型前列腺炎应取前列腺液或前列腺按摩后尿液进行细菌培养,根据培养结果和药敏实验选择敏感抗生素。Ⅲ型前列腺炎的主要治疗目标是缓解疼痛、改善排尿和提高患者生活

中文标题:

合理应用药物治疗前列腺炎的临床专家意见

发布日期:

2018-12-30

简要介绍:

Ⅰ型和Ⅱ型前列腺炎主要由病原体感染引起。慢性细菌性前列腺炎患者的临床分离株中,约85% 具有形成生物膜的能力。生物膜能粘附于前列腺小管上皮细胞,显著减弱了抗生素治疗的效果,成为病原体持续存在和感染复发的重要原因。Ⅰ型前列腺炎应及早进行抗感染治疗。Ⅱ型前列腺炎应取前列腺液或前列腺按摩后尿液进行细菌培养,根据培养结果和药敏实验选择敏感抗生素。Ⅲ型前列腺炎的主要治疗目标是缓解疼痛、改善排尿和提高患者生活质量。由于III 型前列腺炎临床表现的异质性,对患者的深入诊断和评估,对于合理用药和有效治疗非常重要。应以患者的症状为导向进行个体化、多模式治疗,以症状改善作为疗效评价的主要指标,避免只针对单一靶点或机制用药
拓展威廉亚洲博彩公司 :前列腺相关威廉亚洲博彩公司 :

相关资料下载:
[AttachmentFileName(sort=100, fileName=合理应用药物治疗前列腺炎的临床专家意见)] GetToolGuiderByIdResponse(projectId=1, id=46d891c00169522b, title=合理应用药物治疗前列腺炎的临床专家意见, enTitle=, guiderFrom=中国中西医结合外科杂志.2018,24(6):812-814., authorId=null, author=, summary=Ⅰ型和Ⅱ型前列腺炎主要由病原体感染引起。慢性细菌性前列腺炎患者的临床分离株中,约85% 具有形成生物膜的能力。生物膜能粘附于前列腺小管上皮细胞,显著减弱了抗生素治疗的效果,成为病原体持续存在和感染复发的重要原因。Ⅰ型前列腺炎应及早进行抗感染治疗。Ⅱ型前列腺炎应取前列腺液或前列腺按摩后尿液进行细菌培养,根据培养结果和药敏实验选择敏感抗生素。Ⅲ型前列腺炎的主要治疗目标是缓解疼痛、改善排尿和提高患者生活, cover=, journalId=null, articlesId=null, associationId=943, associationName=中国泌尿外科相关专家组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sun Dec 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>Ⅰ型和Ⅱ型前列腺炎主要由病原体感染引起。慢性细菌性前列腺炎患者的临床分离株中,约85% 具有形成生物膜的能力。生物膜能粘附于前列腺小管上皮细胞,显著减弱了抗生素治疗的效果,成为病原体持续存在和感染复发的重要原因。Ⅰ型前列腺炎应及早进行抗感染治疗。Ⅱ型前列腺炎应取前列腺液或前列腺按摩后尿液进行细菌培养,根据培养结果和药敏实验选择敏感抗生素。Ⅲ型前列腺炎的主要治疗目标是缓解疼痛、改善排尿和提高患者生活质量。由于III 型前列腺炎临床表现的异质性,对患者的深入诊断和评估,对于合理用药和有效治疗非常重要。应以患者的症状为导向进行个体化、多模式治疗,以症状改善作为疗效评价的主要指标,避免只针对单一靶点或机制用药</div> <div></div> 拓展威廉亚洲博彩公司 :<strong>与<font color=red>前列腺</font>相关威廉亚洲博彩公司 :</strong><br><ul><li><a href="//www.nyrain.com/guideline/show_article.do?id=91b9d1c00169239d" title="经尿道前列腺等离子电切安全共识" target=_blank>经尿道前列腺等离子电切安全共识</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=831a51c0016e985d" title="超声引导下经直肠前列腺穿刺安全共识" target=_blank>超声引导下经直肠前列腺穿刺安全共识</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=2d17c1c0016e856b" title="2018版转移性前列腺癌诊治中国专家共识" target=_blank>2018版转移性前列腺癌诊治中国专家共识</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=2891d1c001668537" title="黄莪胶囊在良性前列腺增生临床应用中国专家共识" target=_blank>黄莪胶囊在良性前列腺增生临床应用中国专家共识</a></li> <li><a href="//www.nyrain.com/guideline/show_article.do?id=097ae1c00165a93c" title="2018 CUA威廉亚洲博彩公司 :男性下尿路症状/良性前列腺增生(更新版)" target=_blank>2018 CUA威廉亚洲博彩公司 :男性下尿路症状/良性前列腺增生(更新版)</a></li> 更多信息请点击:<a href="//www.nyrain.com/guideline/list.do?q=%E5%89%8D%E5%88%97%E8%85%BA" target=_blank>有关前列腺更多威廉亚洲博彩公司 </a></ul>, tagList=[TagDto(tagId=86137, tagName=合理应用药物), TagDto(tagId=301, tagName=前列腺炎)], categoryList=[CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3987, appHits=338, showAppHits=0, pcHits=2516, showPcHits=1759, likes=78, shares=13, comments=6, approvalStatus=1, publishedTime=Wed Jan 30 23:09:21 CST 2019, publishedTimeString=2018-12-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Jan 30 23:09:21 CST 2019, updatedBy=null, updatedName=null, updatedTime=Mon Jan 01 13:10:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=合理应用药物治疗前列腺炎的临床专家意见)])
合理应用药物治疗前列腺炎的临床专家意见
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1010721, encodeId=14cd1010e215a, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=332a2318615, createdName=yeyekeke, createdTime=Mon Aug 23 21:02:45 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002853, encodeId=a290100285340, content=一直寻找的资料,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6785205858, createdName=1474c43fm46暂无昵称, createdTime=Mon Jul 26 22:11:27 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965303, encodeId=736c965303c9, content=需要下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=302d5490895, createdName=陈晨药师, createdTime=Thu May 13 19:18:21 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965071, encodeId=06009650e1ed, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da725499995, createdName=哈哈三郎, createdTime=Thu May 13 00:36:09 CST 2021, time=2021-05-13, status=1, ipAttribution=)]
    2021-08-23 yeyekeke

    学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1010721, encodeId=14cd1010e215a, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=332a2318615, createdName=yeyekeke, createdTime=Mon Aug 23 21:02:45 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002853, encodeId=a290100285340, content=一直寻找的资料,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6785205858, createdName=1474c43fm46暂无昵称, createdTime=Mon Jul 26 22:11:27 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965303, encodeId=736c965303c9, content=需要下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=302d5490895, createdName=陈晨药师, createdTime=Thu May 13 19:18:21 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965071, encodeId=06009650e1ed, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da725499995, createdName=哈哈三郎, createdTime=Thu May 13 00:36:09 CST 2021, time=2021-05-13, status=1, ipAttribution=)]
    2021-07-26 1474c43fm46暂无昵称

    一直寻找的资料,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1010721, encodeId=14cd1010e215a, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=332a2318615, createdName=yeyekeke, createdTime=Mon Aug 23 21:02:45 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002853, encodeId=a290100285340, content=一直寻找的资料,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6785205858, createdName=1474c43fm46暂无昵称, createdTime=Mon Jul 26 22:11:27 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965303, encodeId=736c965303c9, content=需要下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=302d5490895, createdName=陈晨药师, createdTime=Thu May 13 19:18:21 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965071, encodeId=06009650e1ed, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da725499995, createdName=哈哈三郎, createdTime=Thu May 13 00:36:09 CST 2021, time=2021-05-13, status=1, ipAttribution=)]
    2021-05-13 陈晨药师

    需要下载学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1010721, encodeId=14cd1010e215a, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=332a2318615, createdName=yeyekeke, createdTime=Mon Aug 23 21:02:45 CST 2021, time=2021-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002853, encodeId=a290100285340, content=一直寻找的资料,, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6785205858, createdName=1474c43fm46暂无昵称, createdTime=Mon Jul 26 22:11:27 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965303, encodeId=736c965303c9, content=需要下载学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=302d5490895, createdName=陈晨药师, createdTime=Thu May 13 19:18:21 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965071, encodeId=06009650e1ed, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da725499995, createdName=哈哈三郎, createdTime=Thu May 13 00:36:09 CST 2021, time=2021-05-13, status=1, ipAttribution=)]
    2021-05-13 哈哈三郎

    学习一下

    0